Effective Mar 25, 2026, Incyte announced exec title changes: Pablo J.
Filed with the SEC on · Summarized by InvestorsBot
Effective Mar 25, 2026, Incyte announced exec title changes: Pablo J. Cagnoni → President, Incyte & Global Head of R&D; Steven H. Stein → EVP, Chief Medical Officer & Head of Late‑stage Development; Mohamed Issa → EVP, Head of U.S. Commercial 🧬📅 $INCY #Biotech #Leadership
William J. Meury remains CEO and a director; Pablo Cagnoni replaces him as President. Company says there were no compensation changes for any impacted executives in connection with these title moves. $INCY 💼 #Incyte #CorporateGovernance
Biographies and business experience for the impacted executives are in Incyte’s 10‑K filed Feb 10, 2026. Moves underscore focus on R&D, late‑stage development and U.S. commercial execution—monitor pipeline & U.S. sales strategy. $INCY 🔬📈 #Biotech #R&D